Iolascon A, Andolfo I, Russo R. Congenital dyserythropoietic anemias. Blood. 2020;136(11):1274–83. https://doi.org/10.1182/blood.2019000948.
Roy NBA, Babbs C. The pathogenesis, diagnosis and management of congenital dyserythropoietic anaemia type I. Br J Haematol. 2019;185(3):436–49. https://doi.org/10.1111/bjh.15817.
Article PubMed PubMed Central Google Scholar
Lavabre-Bertrand T, Blanc P, Navarro R, Saghroun M, Vannereau H, Braun M, Wagner A, Taib J, Lavabre-Bertrand C, Navarro M. Alpha-interferon therapy for congenital dyserythropoiesis type I. Br J Haematol. 1995;89(4):929–32. https://doi.org/10.1111/j.1365-2141.1995.tb08442.x.
Article CAS PubMed Google Scholar
Russo R, Andolfo I, Manna F, Gambale A, Marra R, Rosato BE, Caforio P, Pinto V, Pignataro P, Radhakrishnan K, Unal S, Tomaiuolo G, Forni GL, Iolascon A. Multi-gene panel testing improves diagnosis and management of patients with hereditary anemias. Am J Hematol. 2018;93(5):672–82. https://doi.org/10.1002/ajh.25058.
Article CAS PubMed Google Scholar
Roy NB, Wilson EA, Henderson S, Wray K, Babbs C, Okoli S, Atoyebi W, Mixon A, Cahill MR, Carey P, Cullis J, Curtin J, Dreau H, Ferguson DJ, Gibson B, Hall G, Mason J, Morgan M, Proven M, Qureshi A, Sanchez Garcia J, Sirachainan N, Teo J, Tedgard U, Higgs D, Roberts D, Roberts I, Schuh A. A novel 33-gene targeted resequencing panel provides accurate, clinical-grade diagnosis and improves patient management for rare inherited anaemias. Br J Haematol. 2016;175(2):318–30. https://doi.org/10.1111/bjh.14221.
Article CAS PubMed PubMed Central Google Scholar
Marwaha RK, Bansal D, Trehan A, Garewal G. Interferon therapy in congenital dyserythropoietic anemia type I/II. Pediatr Hematol Oncol. 2005;22(2):133–8. https://doi.org/10.1080/08880010590907221.
Article CAS PubMed Google Scholar
Wickramasinghe SN, Hasan R, Smythe J. Reduced interferon-alpha production by Epstein-Barr virus transformed B-lymphoblastoid cell lines and lectin-stimulated lymphocytes in congenital dyserythropoietic anaemia type I. Br J Haematol. 1997;98(2):295–8. https://doi.org/10.1046/j.1365-2141.1997.1993016.x.
Article CAS PubMed Google Scholar
Agrigento V, Barone R, Sclafani S, Di Maggio R, Sacco M, Maggio A, D’Alcamo E. Response to alpha-interferon treatment of the congenital dyserythropoietic anemia type I in two Sicilian beta thalassemia carriers. Indian J Hematol Blood Transfus. 2017;33(4):621–3. https://doi.org/10.1007/s12288-016-0765-9.
Article CAS PubMed Google Scholar
Lavabre-Bertrand T, Ramos J, Delfour C, Henry L, Guiraud I, Carillo S, Wagner A, Bureau JP, Blanc P. Long-term alpha interferon treatment is effective on anaemia and significantly reduces iron overload in congenital dyserythropoiesis type I. Eur J Haematol. 2004;73(5):380–3. https://doi.org/10.1111/j.1600-0609.2004.00310.x.
Rathe M, Moller MB, Greisen PW, Fisker N. Successful management of transfusion-dependent congenital dyserythropoietic anemia type 1b with interferon alfa-2a. Pediatr Blood Cancer. 2018;65(3): e26866. https://doi.org/10.1002/pbc.26866.
Wickramasinghe SN. Response of CDA type I to alpha-interferon. Eur J Haematol. 1997;58(2):121–3. https://doi.org/10.1111/j.1600-0609.1997.tb00935.x.
Article CAS PubMed Google Scholar
Babbs C, Roberts NA, Sanchez-Pulido L, McGowan SJ, Ahmed MR, Brown JM, Sabry MA, Consortium WGS, Bentley DR, McVean GA, Donnelly P, Gileadi O, Ponting CP, Higgs DR, Buckle VJ. Homozygous mutations in a predicted endonuclease are a novel cause of congenital dyserythropoietic anemia type I. Haematologica. 2013;98(9):1383–7. https://doi.org/10.3324/haematol.2013.089490.
Ask K, Jasencakova Z, Menard P, Feng Y, Almouzni G, Groth A. Codanin-1, mutated in the anaemic disease CDAI, regulates Asf1 function in S-phase histone supply. EMBO J. 2012;31(8):2013–23. https://doi.org/10.1038/emboj.2012.55.
Article CAS PubMed PubMed Central Google Scholar
Pockros PJ, Carithers R, Desmond P, Dhumeaux D, Fried MW, Marcellin P, Shiffman ML, Minuk G, Reddy KR, Reindollar RW, Lin A, Brunda MJ, Group PIS. Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial. Am J Gastroenterol. 2004;99(7):1298–305. https://doi.org/10.1111/j.1572-0241.2004.30306.x.
Huang YW, Qin A, Fang J, Wang TF, Tsai CW, Lin KC, Teng CL, Larouche R. Novel long-acting ropeginterferon alfa-2b: pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial. Br J Clin Pharmacol. 2022;88(5):2396–407. https://doi.org/10.1111/bcp.15176.
Article CAS PubMed Google Scholar
Lee N, Erdos K, Abdul Rahman A, Silver RT, Scandura JM, Abu-Zeinah G. Ropeginterferon alfa-2b (ROPEG) and peginterferon alfa-2a (PEG) at low dose with response-based titration (LDRT) have comparable efficacy and tolerability in polycythemia vera (PV). Blood. 2024;144:4568. https://doi.org/10.1182/blood-2024-211143.
Essers MA, Offner S, Blanco-Bose WE, Waibler Z, Kalinke U, Duchosal MA, Trumpp A. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature. 2009;458(7240):904–8. https://doi.org/10.1038/nature07815.
Article CAS PubMed Google Scholar
Zoumbos NC, Gascon P, Djeu JY, Young NS. Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo. Proc Natl Acad Sci U S A. 1985;82(1):188–92. https://doi.org/10.1073/pnas.82.1.188.
Article CAS PubMed PubMed Central Google Scholar
Libregts SF, Gutierrez L, de Bruin AM, Wensveen FM, Papadopoulos P, van Ijcken W, Ozgur Z, Philipsen S, Nolte MA. Chronic IFN-γ production in mice induces anemia by reducing erythrocyte life span and inhibiting erythropoiesis through an IRF-1/PU.1 axis. Blood. 2011;118(9):2578–88. https://doi.org/10.1182/blood-2010-10-315218.
Article CAS PubMed Google Scholar
Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, Wolf D, Kralovics R, Gisslinger B, Strecker K, Egle A, Melchardt T, Burgstaller S, Willenbacher E, Schalling M, Them NC, Kadlecova P, Klade C, Greil R. Ropeginterferon alfa-2b, a novel IFNalpha-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015;126(15):1762–9. https://doi.org/10.1182/blood-2015-04-637280.
Article CAS PubMed PubMed Central Google Scholar
Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Rossiev V, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Grohmann-Izay B, Hasselbalch HC, Kralovics R, Kiladjian JJ, Group P-PS. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7(3):e196–208. https://doi.org/10.1016/S2352-3026(19)30236-4.
Miyachi N, Zagrijtschuk O, Kang L, Yonezu K, Qin A. Pharmacokinetics and pharmacodynamics of Ropeginterferon Alfa-2b in healthy Japanese and Caucasian subjects after single subcutaneous administration. Clin Drug Investig. 2021;41(4):391–404. https://doi.org/10.1007/s40261-021-01026-5.
Article CAS PubMed Google Scholar
Shamseddine A, Taher A, Jaafar H, Haidar JH, Nasr R, Arzoumanian V, Salem Z, Bazarbachi A. Interferon alpha is an effective therapy for congenital dyserythropoietic anaemia type I. Eur J Haematol. 2000;65(3):207–9. https://doi.org/10.1034/j.1600-0609.2000.9c244.x.
Comments (0)